Teva announced the availability of a new liquid formulation of Treanda (bendamustine HCl) Injection.
Prior to the new formulation approval, Treanda was available as vials containing lyophilized powder for reconstitution.
The liquid formulation now removes the reconstitution step, reducing the preparation time for healthcare professionals. The liquid formulation will be replacing the lyophilized powder formulation moving forward.
Treanda is an alkylating agent approved for the treatment of chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab or a rituximab–containing regimen.
RELATED: New Strategy to Classify Differences in Risk for Chronic Lymphocytic Leukemia
The exact mechanism of action is unknown but bendamustine is thought to be active against both quiescent and dividing cells. Preclinical studies suggest that it may lead to cell death by a process known as apoptosis as well as by an alternate cell death pathway which disrupts normal cell division known as mitotic catastrophe.
Treanda Injection is supplied as a 90mg/mL strength in 45mg/0.5mL and 180mg/2mL single-use vials.
For more information call (800) 896-5855 or visit Treanda.com.
This article originally appeared on MPR